Elusys Therapeutics is a biopharmaceutical company founded in Pine Brook, New Jersey in 1998. The company specializes in the development of antibodies for the treatment infectious diseases. Elusys is engaged in the development of new therapies for the treatment of anthrax exposure following a natural or intentional release of anthrax spores. In particular, Elusys is currently focusing on late-stage clinical trials of Anthim (Obiltoxaximab) to be used for treatment and prevention of inhaled anthrax.